文献速递脑血管病

癌症相关缺血性卒中具有独特的血液mRNA表达谱

Cancer-Related Ischemic Stroke Has a Distinct Blood mRNA Expression Profile.
PubMed 文献 · Stroke · 2019-09-12

研究前瞻性纳入4组各10名受试者,比较活动性实体瘤合并急性缺血性卒中(AIS)、仅癌症、仅AIS及仅血管危险因素者的血液mRNA表达谱。癌症-卒中组50%卒中为隐源性,与仅卒中组比较并排除仅癌症基因后,438个基因差异表达,涉及自噬、免疫/炎症及基因调控通路。结论提示癌症相关AIS有独特分子特征。

要点

  • 癌症相关AIS患者血液mRNA表达谱与仅AIS患者不同。
  • 差异基因涉及自噬、免疫/炎症及基因调控通路。
  • 未来需评估血液mRNA能否预测AIS患者隐匿癌症。

核心结论

  • 癌症相关AIS患者血液mRNA表达谱存在独特分子特征。

研究设计与样本

  • 前瞻性纳入4组各10名受试者,2009至2018年于3个中心入组。
  • 组别为活动性实体瘤合并AIS、仅活动性癌症、仅AIS、仅血管危险因素。
  • 仅AIS组和仅癌症组按年龄、性别及癌症类型(如适用)与癌症-卒中组匹配。
  • 血管危险因素组按年龄、性别及血管危险因素与癌症-卒中组和仅卒中组匹配。
  • 卒中后72至120小时采血,行3' mRNA测序,用ANOVA和Fisher最小显著差对比法分析差异表达。

主要发现

  • 癌症-卒中组50%卒中为隐源性。
  • 所有组间均有可区分彼此的差异表达基因。
  • 癌症-卒中组与仅卒中组比较并排除仅癌症基因后,438个基因差异表达。
  • 上调基因/通路涉及自噬信号、免疫/炎症和基因调控,包括IL-1、干扰素、松弛素、mTOR信号、SQSTMI1和CREB1。

临床怎么用

  • 提示癌症相关AIS可能具有可识别的血液mRNA分子特征。
  • 未来需研究血液mRNA能否预测AIS患者中隐匿癌症的检测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background and Purpose- Comorbid cancer is common in patients with acute ischemic stroke (AIS). As blood mRNA profiles can distinguish AIS mechanisms, we hypothesized that cancer-related AIS would have a distinctive gene expression profile. Methods- We evaluated 4 groups of 10 subjects prospectively enrolled at 3 centers from 2009 to 2018. This included the group of interest with active solid tumor cancer and AIS and 3 control groups with active cancer only, AIS only, or vascular risk factors only. Subjects in the AIS-only and cancer-only groups were matched to subjects in the cancer-stroke group by age, sex, and cancer type (if applicable). Subjects in the vascular risk factor group were matched to subjects in the cancer-stroke and stroke-only groups by age, sex, and vascular risk factors. Blood was drawn 72 to 120 hours after stroke. Total RNA was processed using 3' mRNA sequencing. ANOVA and Fisher least significant difference contrast methods were used to estimate differential gene expression between groups. Results- In the cancer-stroke group, 50% of strokes were cryptogenic. All groups had differentially expressed genes that could distinguish among them. Comparing the cancer-stroke group to the stroke-only group and after accounting for cancer-only genes, 438 genes were differentially expressed, including upregulation of multiple genes/pathways implicated in autophagy signaling, immunity/inflammation, and gene regulation, including IL (interleukin)-1, interferon, relaxin, mammalian target of rapamycin signaling, SQSTMI1 (sequestosome-1), and CREB1 (cAMP response element binding protein-1). Conclusions- This study provides evidence for a distinctive molecular signature in blood mRNA expression profiles of patients with cancer-related AIS. Future studies should evaluate whether blood mRNA can predict detection of occult cancer in patients with AIS. Clinical Trial Registration- URL: https://clinicaltrials.gov. Unique identifier: NCT02604667.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Navi BB, Mathias R, Sherman CP, et al. Cancer-Related Ischemic Stroke Has a Distinct Blood mRNA Expression Profile. Stroke. 2019. PMID: 31510897. doi:10.1161/STROKEAHA.119.026143

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。